Molecular Templates
Molecular Templates develops novel therapeutic compounds for cancer.
Employees
Market cap
€6.8m
Enterprise valuation
€6m (Public information from Sep 2024)
Share price
$1.36 MTEM
Georgetown Texas (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 19.5m | 15.6m | 38.7m | 19.8m | 52.6m | 12.3m | 1.3m |
% growth | - | (20 %) | 148 % | (49 %) | 166 % | (77 %) | (90 %) |
EBITDA | (46.0m) | (99.8m) | (80.1m) | (87.9m) | (2.6m) | - | - |
% EBITDA margin | (236 %) | (638 %) | (207 %) | (445 %) | (5 %) | - | - |
Profit | (69.4m) | (105m) | (83.0m) | (92.7m) | (8.1m) | (21.3m) | (33.4m) |
% profit margin | (356 %) | (671 %) | (215 %) | (469 %) | (15 %) | (173 %) | (2654 %) |
EV / revenue | 36.3x | 25.0x | 2.9x | 0.9x | 0.4x | 0.8x | 8.0x |
EV / EBITDA | -15.4x | -3.9x | -1.4x | -0.2x | -7.7x | - | - |
R&D budget | 50.5m | 93.0m | 84.7m | 82.4m | 48.9m | - | - |
R&D % of revenue | 259 % | 595 % | 219 % | 417 % | 93 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$2.5m | Series A | ||
$1.4m | Early VC | ||
N/A | $10.6m | Grant | |
$7.0m | Early VC | ||
$3.5m | Series C | ||
N/A | Series D | ||
N/A | N/A | IPO | |
$60.0m | Post IPO Equity | ||
* | $9.5m | Private Placement VC | |
Total Funding | €31.4m |
Recent News about Molecular Templates
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Molecular Templates
EditACQUISITION by Molecular Templates Aug 2017